RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · IEX Real-Time Price · USD
7.86
-0.09 (-1.13%)
At close: Apr 22, 2024, 4:00 PM
7.94
+0.08 (1.02%)
Pre-market: Apr 23, 2024, 6:24 AM EDT

RAPT Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Revenue
01.533.815.04000
Revenue Growth (YoY)
--59.95%-24.38%----
Gross Profit
01.533.815.04000
Selling, General & Admin
26.0620.2416.0412.778.725.183.71
Research & Development
10167.0856.9945.4934.9131.7725.62
Operating Expenses
127.0687.3273.0258.2643.6336.9529.33
Operating Income
-127.06-85.8-69.21-53.21-43.63-36.95-29.33
Other Expense / Income
-10.26-1.96-0.01-1.31-1.29-0.8-0.22
Pretax Income
-116.8-83.84-69.2-51.9-42.34-36.15-29.12
Income Tax
0000.990.6600
Net Income
-116.8-83.84-69.2-52.89-43-36.15-29.12
Shares Outstanding (Basic)
38332724410
Shares Outstanding (Diluted)
38332724410
Shares Change
17.82%18.80%13.49%455.27%598.45%44.16%-
EPS (Basic)
-3.05-2.58-2.53-2.19-9.89-58.09-67.45
EPS (Diluted)
-3.05-2.58-2.53-2.19-9.89-58.09-67.45
Free Cash Flow
-98.17-71.62-61.78-40.89-36.32-36.45-28.25
Free Cash Flow Per Share
-2.56-2.20-2.26-1.69-8.36-58.58-65.44
Gross Margin
-100.00%100.00%100.00%---
Operating Margin
--5618.53%-1815.08%-1055.41%---
Profit Margin
--5490.37%-1814.95%-1049.03%---
Free Cash Flow Margin
--4689.98%-1620.27%-810.97%---
EBITDA
-113.25-81.03-68.21-50.78-41.01-34.91-27.73
EBITDA Margin
--5306.55%-1788.83%-1007.12%---
Depreciation & Amortization
3.552.8111.121.331.241.38
EBIT
-116.8-83.84-69.2-51.9-42.34-36.15-29.12
EBIT Margin
--5490.37%-1814.95%-1029.39%---
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).